Risk-based treatment study for children with rhabdomyosarcoma
Part of Cancer clinical trials.
This study tests different treatment plans for children with rhabdomyosarcoma based on their individual risk factors. It aims to find the best therapy for each child, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be under 18 years old
- Diagnosed with rhabdomyosarcoma through biopsy or bone marrow test
- Receiving cancer treatment for the first time
- Must be well enough to perform daily activities (ECOG score of 0, 1, or 2)
- Life expectancy of at least 8 months
- Parent or guardian must sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding all-trans retinoic acid to a standard chemotherapy regimen (VAC) can improve outcomes for people with intermediate-to-high-risk rhabdomyosarcoma. It is for those who have not had prior cancer drug treatment and have adequate organ function.
This study uses a special machine to find unique protein patterns in rhabdomyosarcoma tumor samples from children and young adults. By analyzing leftover tissue from past biopsies or surgeries, researchers hope to better understand the disease and improve future treatments.
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Hear when a new Rhabdomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.